With the flu virus thriving in crowded areas, exposure is almost inevitable. It can also linger on contaminated surfaces in high-traffic areas like restaurants and airports. Certain factors, including stress and weakened immune systems, can further increase susceptibility.
Although they're often associated with mild symptoms, Influenza can still pose a significant health threat, especially for immunocompromised individuals. According to recent data from the Centers for Disease Control and Prevention (CDC), the estimated number of flu-related deaths for the 2024 to 2025 season so far is at least 22,000.
Dr. Timothy Craig, professor of the Department of Medicine Division of Pulmonary, Allergy, and Critical Care Medicine at Penn State University, emphasized that vaccines play a crucial role in reducing disease severity and the risk of long-term complications. In the case of COVID-19, vaccines not only reduce severe immediate complications but also limit its long-term effects.
As flu season continues to affect millions across the United States, early and accurate diagnosis remains crucial for recovery and public health. Flu symptoms typically appear within one to four days of exposure. However, many individuals initially downplay early signs, mistaking them for allergies or minor irritations. This uncertainty often delays necessary precautions and treatment, increasing the risk of transmission.
Historically, obtaining a flu diagnosis required a visit to a doctor's office—a time-consuming process that deterred many from seeking confirmation. This challenge was particularly pronounced in rural areas, where healthcare resources are limited, and peak flu season coincides with holiday-related clinic closures.
The introduction of rapid antigen tests has significantly improved access to flu diagnosis. These tests, which played a pivotal role in detecting COVID-19 cases, are now available for influenza as well. In February 2023, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a range of over-the-counter combinational influenza and COVID-19 diagnostic tests, starting with Lucira and later expanding to others such as iCare, WELLlife, and more.
Dr. Craig also emphasized the usefulness of rapid testing kits in distinguishing between flu and COVID-19 infections. These at-home kits, available at pharmacies and online retailers, allow individuals to test themselves without a prescription.
Many of these tests are combination kits that detect Influenza A, Influenza B, and COVID-19—three respiratory illnesses with overlapping symptoms. Since treatments vary for each virus, early detection helps ensure individuals receive the most effective care as soon as possible.
A national push is underway to increase public awareness and build partnerships with communities, healthcare professionals, and other stakeholders to promote education and access to these tests. Dr. Craig supports this initiative, viewing it as a key strategy to control the spread of infectious diseases.
